ABOUT HIGHTIDE

East Meets West - the Quest for Cure

Who We Are

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs.  The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).  HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. for both NASH and PSC, as well as Orphan Drug designation for PSC.  In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Our Mission

Mission:Focus on patient‑centric drug development to bring total and optimal benefits to patients

Vision:  Become a leading and respected globally integrated biotech company

Value

· Simplicity is the ultimate sophistication 

· Mind and hand

· All for one and one for all, united we stand 

· Resilient growth 

· Think win/win

Leadership Team

Scientific Advisory Board and Experts

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

We will contact you as soon as possible

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

© 2024 HighTide Therapeutics, Inc.

Legal StatementPrivacy PolicyCookie Policy

收起

Follow Us

© 2024 HighTide Therapeutics, Inc.